Standardization of in vitro assays to evaluate the activity of polyherbal siddha formulations against Chikungunya virus infection
Chikungunya, a viral fever caused by Aedes mosquito results in extreme morbidity in affected individuals and is a major public health concern in India. Currently, modern vaccines or formulations prescribed by physicians can only provide symptomatic relief for the pyretic and post pyretic phase of the disease. Siddha practitioners follows strict medical regimen based on traditional Indian knowledge/concepts to treat Chikungunya with considerable results. The current study was undertaken to standardize assays for the study of these siddha formulations and to check their efficacy and potential mode of action as antivirals for Chikungunya virus infection in in vitro system. Although, siddha practitioners follow a regime containing 4–6 formulations, of these Brahmanandha bairavam mathirai, a part of the regime for Chikungunya followed at National Institute of Siddha and Vishnu chakram along with Brahmanandha bairavam mathirai, a part of Thiruchergodu Regime were found of have antiviral activities. It was observed that both Vishnu chakram and Brahmanandha bairavam mathirai were equally effective in blocking Chikungunya virus from entering susceptible cells in the concentrations range of 0.0625 and 0.5 mg/ml. Additionally, it was also observed that Brahmanandha bairavam mathirai was more effective than Vishnu chakram against entry of Chikungunya in the cells. The assays used in this study provides insights to the possible mode of action of various formulations used by siddha practitioners for the treatment of Chikungunya infection.
KeywordsPolyherbal Siddha formulations Chikungunya In vitro
We are thankful to Dr. Sathya Rajeshwaran, Siddha Central Research Institute, Chennai, for his inputs regarding approved siddha regimes. We acknowledge Dr. Vimal Narayanan’s assistance in the preparation of supplementary table. Financial support for the study was received from the Ministry of Ayush, (Grant No: ND/AYU/15/019), Government of India and their support is duly acknowledged.
- 2.Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al. Estimating Chikungunya prevalence in La Reunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect Dis. 2008;8:99. https://doi.org/10.1186/1471-2334-8-99.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Volk SM, Chen R, Tsetsarkin KA, Adams AP, Garcia TI, Sall AA, et al. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J Virol. 2010;84(13):6497–504. https://doi.org/10.1128/JVI.01603-09.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Thirunarayanan T. An introduction to siddha medicine. Tiruchendur: Thirukumaran Publishers; 1981.Google Scholar
- 18.Lavekar G, Padhi M. Management of chikungunya through ayurveda and siddha a technical_report. New Delhi: Central Council for Research in Ayurveda and Siddha; 2009.Google Scholar
- 19.Lavekar G, Padhi M. Management of chikungunya through ayurveda and siddha: a technical report. New Delhi: Central Council for Research in Ayurveda and Siddha; 2007. p. 28–44.Google Scholar
- 23.Ramya Devi D, Sandhya P, Malarvizhi K, Subashri S, Abinaya M, Vedha Hari B. Development of ayurvedic and siddha medicine through the application of modern pharmaceutical technique. Curr Trends Biotechnol Pharm. 673Google Scholar
- 27.Kaur P, Thiruchelvan M, Lee RC, Chen H, Chen KC, Ng ML, et al. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother. 2013;57(1):155–67. https://doi.org/10.1128/AAC.01467-12.CrossRefPubMedPubMedCentralGoogle Scholar